WALTHAM, Mass.– Vicarious Surgical Inc. (NYSE: RBOT), a robotics technology company focused on transforming the field of minimally invasive surgery, has announced the election of two new directors, Fuad Ahmad and Joseph Doherty, to its Board of Directors. The appointments were made during the company’s 2025 Annual Meeting of Stockholders held on June 27.
The company also confirmed the departure of long-serving board member Ric Fulop, who stepped down at the conclusion of the meeting after five years of service.
Vicarious Surgical CEO and co-founder Adam Sachs welcomed the new board members, emphasizing the strategic value they bring as the company moves closer to initiating clinical trials and preparing for commercialization.
“Fuad and Joseph bring decades of leadership experience in medical technology and business transformation that will be essential as we enter the next phase of growth,” Sachs said. “I also want to thank Ric Fulop for his guidance and commitment over the past five years, which have left a lasting positive impact on our company.”
Fuad Ahmad currently serves as a partner at FLG Partners, a financial advisory firm, and has previously held CFO roles at several public companies, including Iridex Corporation, Vaxart, and Globalstar. He brings deep experience in corporate finance, IPOs, and growth strategy. He holds a bachelor’s degree in finance from Brigham Young University.
Joseph Doherty is the CEO of Worcester City Campus Corporation and has an extensive background in healthcare and education. He has held leadership roles at Scapa Healthcare, Olympus Surgical Technologies, and Johnson & Johnson, where he spent more than two decades. Doherty also sits on the board of Immertec, a healthcare training software firm, and holds engineering and MBA degrees from West Point and Nichols College, respectively.
The board changes come as Vicarious Surgical continues to position itself as a pioneer in robotic surgery, combining virtual reality and advanced miniaturized robotics to improve surgical precision and outcomes.
